DT01

DT01 is an investigational oral pharmaceutical product developed by the Centre of Clinical Pharmacology at Hanoi Medical University. It is specifically designed for the treatment of irritable bowel syndrome with diarrhea (IBS-D). As of 2024, it is undergoing Phase II clinical evaluation (NCT05443490) to determine its efficacy and safety compared to placebo. The treatment regimen involves oral administration of tablets three times daily for a period of eight weeks. The drug aims to address the symptomatic burden of IBS-D, including abdominal pain and stool consistency. While the specific chemical composition is not publicly detailed in international registries, the 'DT' prefix in Vietnamese clinical research typically denotes a standardized traditional or herbal medicine formulation being developed under modern pharmaceutical standards.

Other names

DT01 tabletsDT-01 tabletsDT 01 tablets